Differential Diagnostic Value of Peripheral Blood miR-200b-3p and miR-181b-5p Combined with Multi-Slice Spiral CT Perfusion Scan for Benign Prostatic Hyperplasia and Prostate Cancer
MENG Shengjin
Luwan Branch,Ruijin Hospital, Shanghai Jiaotong University School of Medicine,Shanghai 200020
Abstract：【Objective】To explore the differential value of multi-slice spiral CT (MSCT) perfusion scan combined with serum microRNA-200b-3p (miR-200b-3p) and microRNA-181b-5p (miR-181b-5p) in benign prostatic hyperplasia (BPH) and prostate cancer. 【Methods】A total of 249 patients with prostate lesions admitted to our hospital from May 2021 to September 2023 were selected and divided into BPH group (n=144) and prostate cancer group (n=105) based on pathological results. Logistic regression analysis was used to investigate the relationship between serum miR-200b-3p, miR-181b-5p, and MSCT perfusion parameters with prostate cancer. A receiver operating characteristic curve was plotted to analyze the diagnostic value of MSCT perfusion parameters combined with serum miR-200b-3p and miR-181b-5p for prostate cancer. 【Results】The serum miR-200b-3p levels in the prostate cancer group were higher than those in the BPH group, while the serum miR-181b-5p levels were lower than those in the BPH group (P<0.05). The rBF and PS of patients in the prostate cancer group were significantly higher than those in the BPH group (P<0.05). The area under the curve of rBF, PS, miR-200b-3p, and miR-181b-5p for single and combined diagnosis of prostate cancer were 0.780, 0.760, 0.763, 0.801, and 0.932, respectively. The results of logistic regression analysis showed that rBF>50.54 mL/(min?100 g), PS>28.82 mL/(min?100 g),miR-200b-3p>1.23 were independent risk factors affecting the occurrence of prostate cancer (P<0.05); MiR-181b-5p<0.90 is a protective factor affecting the occurrence of prostate cancer (P<0.05). 【Conclusion】 The combination of MSCT perfusion imaging parameters and serum miR-200b-3p and miR-181b-5p detection can provide reliable basis for the differential diagnosis of BPH and prostate cancer.
[1] SU Z Y, WANG G H, LI L L. CHRDL1, NEFH, TAGLN and SYNM as novel diagnostic biomarkers of benign prostatic hyperplasia and prostate cancer[J].Cancer Biomark,2023, 38(2):143-159.
[2] GE Y Q, XU B, CAI H Z, et al. Diagnostic role of plasma ORM2 in differentiating prostate cancer from benign prostatic hyperplasia[J].J Cancer Res Clin Oncol,2023, 149(6):2301-2310.
[3] YIN J J, HU X, HU S, et al. Efficacy of multi-slice spiral computed tomography in evaluating gastric cancer recurrence after endoscopic submucosal dissection[J].World J Gastrointest Oncol,2023, 15(9):1636-1643.
[4] KHAN M M, SHARMA V, SERAJUDDIN M. Emerging role of miRNA in prostate cancer: A future era of diagnostic and therapeutics[J].Gene,2023, 888(1):1-13.
[5] PEŁKA K, KLICKA K, GRZYWA T M, et al. miR-96-5p, miR-134-5p, miR-181b-5p and miR-200b-3p heterogenous expression in sites of prostate cancer versus benign prostate hyperplasia-archival samples study[J].Histochem Cell Biol,2021, 155(3):423-433.
[6] MOHLER J L, ANTONARAKIS E S, ARMSTRONG A J, et al. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology[J].J Natl Compr Canc Netw,2019, 17(5):479-505.
[7] BERGENGREN O, PEKALA K R, MATSOUKAS K, et al. 2022 update on prostate cancer epidemiology and risk factors-a systematic review[J].Eur Urol,2023, 84(2):191-206.
[8] PARKIN C J, GILBOURD D, GRILLS R, et al. Transrectal ultrasound-guided prostate needle biopsy remains a safe method in confirming a prostate cancer diagnosis: a multicentre Australian analysis of infection rates[J].World J Urol,2022, 40(2):453-458.
[9] MOHSEN N. Role of MRI, ultrasound, and computed tomography in the management of prostate cancer[J].PET Clin,2022, 17(4):565-583.
[10] XIANG Y S, ZHANG M, ZHAO W Y, et al. Differentiation of localized pneumonic-type lung adenocarcinoma from localized pulmonary inflammatory lesion based on clinical data and multi-slice spiral computed tomography imaging features[J].Transl Cancer Res,2023, 12(1):113-124.
[11] 李友芳, 杨小杰, 张栋, 等. 良性前列腺增生与前列腺肿瘤MSCT征象及鉴别诊断分析[J].中国CT和MRI杂志, 2021, 19(2):112-113.
[12] 王绍丹. 64排CT灌注成像在前列腺癌与良性前列腺增生中的鉴别诊断研究[J].重庆医学, 2022, 51(2):305-307.
[13] DUFFY M J. Biomarkers for prostate cancer: prostate-specific antigen and beyond[J].Clin Chem Lab Med,2020, 58(3):326-339.
[14] XIA L, HAN Q, CHI C F, et al. Transcriptional regulation of PRKAR2B by miR-200b-3p/200c-3p and XBP1 in human prostate cancer[J].Biomed Pharmacother,2020, 124(1):1-13.
[15] XIE X, SUN F K, HUANG X, et al. A circular RNA, circSMARCA5, inhibits prostate cancer proliferative, migrative, and invasive capabilities via the miR-181b-5p/miR-17-3p-TIMP3 axis[J].Aging (Albany NY),2021, 13(15):19908-19919.
2024, Vol. 41 
